What is the recommended evaluation and management for a pregnant patient experiencing extreme anxiety?

Management of Extreme Anxiety During Pregnancy

Screen for anxiety using validated tools, counsel about risks of untreated anxiety versus treatment, and initiate sertraline at 25-50 mg daily as first-line pharmacotherapy if moderate-to-severe symptoms are present, while simultaneously providing cognitive behavioral therapy. 1, 2

Initial Assessment and Screening

• Screen all pregnant patients for anxiety disorders using validated instruments, as recommended for women and adolescent girls aged 13 years or older, including pregnant and postpartum women 1
• Evaluate for specific anxiety disorder types: generalized anxiety disorder, panic disorder, social anxiety disorder, and pregnancy-specific anxiety 1
• Assess for comorbid depression, as 56% of patients with major depressive disorder have comorbid anxiety disorders, and this significantly increases suicide risk 1
• Screen for intimate partner violence, substance use (alcohol, tobacco, drugs), and psychosocial stressors 1
• Review all current medications for teratogenic agents and switch to safer alternatives when possible, using the fewest medications at the lowest effective doses 1

Risk Counseling: Untreated Anxiety vs. Treatment

Counsel patients that untreated anxiety during pregnancy poses significant risks including:

• Adverse birth outcomes (preterm birth, low birth weight) 1
• Impaired maternal-infant bonding and relationship 2
• Decreased breastfeeding initiation 2
• Harm to the mother-infant dyad 2

Pregnancy-specific anxiety is particularly potent in causing adverse maternal and offspring outcomes, more so than general life stress 1

Treatment Algorithm

Mild Anxiety

• Begin with non-pharmacological interventions: structured exercise programs, social support mobilization 3
• Initiate evidence-based psychotherapy: cognitive behavioral therapy (CBT), interpersonal therapy, or mindfulness-based cognitive therapy 3, 4
• Monitor closely for symptom progression within two weeks; escalate to pharmacotherapy if no improvement 3

Moderate-to-Severe Anxiety

• Initiate sertraline 25-50 mg daily as first-line pharmacotherapy due to minimal breast milk excretion and low infant-to-maternal plasma concentration ratios 2
• Combine medication with CBT or other evidence-based psychotherapy for optimal outcomes 3, 4
• Use the lowest effective dose throughout pregnancy and continue treatment rather than discontinuing, as withdrawal may harm the mother-infant dyad 2
• Titrate sertraline slowly upward while monitoring the patient 2

Alternative Medication Considerations

• Consider citalopram as second-line if sertraline is not tolerated or ineffective 2
• Avoid paroxetine specifically due to FDA pregnancy category D classification and cardiac malformation concerns 2
• For patients requiring treatment of co-occurring depression, bupropion could be considered, though it is less efficacious for anxiety disorders than SSRIs 2

Medication Safety Counseling

SSRI Use During Pregnancy

• No increased risk of cardiac malformations with first-trimester sertraline use in large population-based studies 2
• Third-trimester SSRI exposure may cause transient neonatal symptoms (irritability, jitteriness, tremors, feeding difficulty, sleep disturbance, respiratory distress) appearing within hours to days after birth and typically resolving within 1-2 weeks 2
• Late pregnancy SSRI exposure has possible association with persistent pulmonary hypertension of the newborn (PPHN) with number needed to harm of 286-351 2
• Converging evidence suggests that observed associations between prenatal antidepressant exposure and neurodevelopmental problems (autism spectrum disorder, ADHD) are largely due to confounding factors (maternal psychiatric illness) rather than causal medication effects 2

Breastfeeding Considerations

• Continue sertraline during breastfeeding, as it is minimally excreted in breast milk (providing infant <10% of maternal daily dose) 2
• Do not discontinue either breastfeeding or medication, as benefits of breastfeeding are well-documented and untreated maternal anxiety poses significant risks 2

Monitoring and Follow-Up

During Pregnancy

• Continue regular prenatal monitoring including fetal growth assessment, maternal blood pressure, and appropriate maternal weight gain 2
• Reassess anxiety symptoms regularly using validated scales 3

Postpartum Period

• Arrange early follow-up after initial hospital discharge for infants exposed to SSRIs 2
• Monitor infants for signs of drug toxicity or withdrawal over the first week of life, including adequate weight gain and developmental milestone achievement 2
• In severely affected infants with persistent symptoms, a short-term course of chlorpromazine has provided measurable relief 2

Common Pitfalls to Avoid

• Do not avoid treatment altogether due to fear of medication risks, as untreated maternal anxiety carries substantial documented risks to both mother and infant 2
• Do not abruptly discontinue SSRIs during pregnancy, as women who discontinue antidepressants show significantly increased relapse risk of major depression 2
• Do not switch from one SSRI to another with a washout period in most cases; transition directly to prevent depressive relapse while monitoring for withdrawal symptoms 2
• Avoid focusing solely on general life stress; specifically assess and address pregnancy-specific anxiety, as it is more strongly associated with adverse outcomes 1

Special Considerations

• Benzodiazepines (e.g., clonazepam) cross the placenta and may be associated with neonatal withdrawal symptoms (irritability, tremors, feeding difficulties); use requires close monitoring and consideration of gradual tapering if clinically appropriate 5
• Partner support during pregnancy predicts maternal distress levels; consider involving the partner in treatment planning and psychoeducation 1
• Provide psychoeducation about illness course and warning signs as an additional supportive intervention 3